PTHS AMEX
Pelthos Therapeutics Inc.
1W: -7.2%
1M: -17.7%
3M: -15.3%
YTD: -30.1%
1Y: -23.7%
$20.60
+0.25 (+1.23%)
Weekly Expected Move ±10.3%
$16
$18
$21
$23
$25
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
30 relationships30
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2024-02-22
Earliest Filing
2026-01-02
Latest Filing
partner: 17
investor: 6
supplier: 4
target: 3
Counterparties (Filed by PTHS)
30 relationshipsCompanies named in PTHS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Hatchtech Pty Ltd | — | target | Seller of Xeglyze Product assets and intellectual property to Pelthos Therapeutics Inc. | 2026-01-02 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | investor | Investor in convertible note financing and collateral agent | 2025-11-07 | View |
| Sato Pharmaceutical Co., Ltd | — | partner | Counterparty to royalty and milestone payment agreements | 2025-11-07 | View |
| Biofrontera Inc. | BFRIW | supplier | Seller of Xepi assets and intellectual property | 2025-11-07 | View |
| Ferrer Internacional, S.A. | — | supplier | License grantor and API supplier for Xepi | 2025-11-07 | View |
| Interquim, S.A.U. | INTR | supplier | API supplier for Xepi | 2025-11-07 | View |
| Channel Pharmaceutical Corporation | — | partner | Seller party in Channel Products Royalty Agreement | 2025-11-07 | View |
| Nomis RoyaltyVest LLC | — | partner | Purchaser in Channel Products Royalty Agreement | 2025-11-07 | View |
| Madison Royalty LLC | — | partner | Purchaser in Channel Products Royalty Agreement | 2025-11-07 | View |
| LNHC, Inc. | — | partner | Assignor of rights to Ligand | 2025-11-07 | View |
| Sato Pharmaceutical Co., Ltd. | — | partner | Licensee for drug candidates in Japan. | 2025-09-16 | View |
| Madison Royalty LLC | — | investor | Investor in royalty payments on behalf of management team. | 2025-09-16 | View |
| Nomis RoyaltyVest LLC | — | investor | Investor in the PIPE Financing and royalty payments. | 2025-09-16 | View |
| Reedy Creek Investments LLC | — | investor | Investor providing funding for development activities. | 2025-09-16 | View |
| Orion Corporation | ORN | supplier | Manufacturer of the Company's finished drug product, ZELSUVMI. | 2025-09-16 | View |
| LNHC, Inc. | — | target | Target company in the merger with Pelthos Therapeutics Inc. | 2025-09-16 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Parent of LNHC and partner in the merger and licensing agreements. | 2025-09-16 | View |
| Novan, Inc. | NOVTU | partner | Company whose assets were acquired by Ligand and subsequently held by LNHC. | 2025-09-16 | View |
| University of North Carolina at Chapel Hill | — | partner | Licensor of intellectual property rights to the Company. | 2025-09-16 | View |
| CHRO Merger Sub, Inc. | — | partner | Wholly owned subsidiary of the Company used in the merger transaction | 2025-07-02 | View |
| Madison Royalty LLC | — | partner | Counterparty in royalty agreements for Channel Products | 2025-07-02 | View |
| LNHC, Inc. | — | partner | Target company in the merger and PIPE investor | 2025-07-02 | View |
| Nomis RoyaltyVest LLC | — | partner | Counterparty in royalty agreements for ZELSUVMI and Channel Products | 2025-07-02 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Parent company of LNHC and PIPE investor in the merger and financing | 2025-07-02 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Parent company of LNHC and participant in the PIPE Financing. | 2025-04-17 | View |
| Nomis Bay Ltd | — | investor | PIPE investor subscribing for Series A Preferred Stock. | 2025-04-17 | View |
| LNHC, Inc. | — | target | Target company in the merger agreement with Channel Therapeutics Corporation. | 2025-04-17 | View |
| Tikkun Capital LLC | — | investor | Committed to purchase up to $30,000,000 of Common Stock under a committed equity financing facility. | 2024-07-29 | View |
| A.G.P./Alliance Global Partners | — | partner | Representative of underwriters for the Initial Public Offering | 2024-02-22 | View |
| NYSE American LLC | — | partner | Exchange where the Common Stock commenced trading | 2024-02-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-08-13 | Financial Restatement | View | |
| 2026-08-13 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-05-28 | Regulation FD; Exhibits | View | |
| 2026-05-21 | Accountant Change; Officer/Director Change; Exhibits | View | |
| 2026-05-14 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-14 | Regulation FD; Exhibits | View | |
| 2026-04-10 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-01-13 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2026-01-12 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure | View | |
| 2026-01-02 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-23 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-12-17 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-07 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-10-14 | Regulation FD Disclosure | View | |
| 2025-09-16 | Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition; F | Acquisition | View |
| 2025-09-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-18 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-02 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Creati | Agreement Acquisition | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR